Evidence map›Paper›PMID 30988278›Full record

ArticleCell death & disease2019

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.

Shiyao Sui, Jian Zhang, Shouping Xu, Qin Wang, Peiyuan Wang, Da Pang

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 223 citations in OpenAlex.

  1. PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shiyao SuiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, 150081, Harbin, China.
Jian ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, 150081, Harbin, China.
Shouping XuDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, 150081, Harbin, China.
Qin WangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, 150081, Harbin, China.
Peiyuan WangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, 150081, Harbin, China.
Da PangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, 150081, Harbin, China. pangda@ems.hrbmu.edu.cn.
Third Affiliated Hospital of Harbin Medical University · CNHeilongjiang Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(+)-JQ1 is an inhibitor of the tumor-driver bromodomain protein BRD4 and produces satisfactory effects because it efficiently increases apoptosis. Ferroptosis is an oxidative cell death program differing from apoptosis. Ferroptosis is characterized by high levels of iron and reactive oxygen species and has been confirmed to suppress tumor growth. In this study, BRD4 expression in cancer and its influence on the prognosis of cancer patients were analyzed using data from public databases. In addition, the effect of the BRD4 inhibitor (+)-JQ1 on ferroptosis was investigated via a series of in vitro assays. A nude mouse model was used to evaluate the function of (+)-JQ1 in ferroptosis in vivo. The potential mechanisms by which (+)-JQ1 regulates ferroptosis were explored. The results showed that BRD4 expression levels were higher in cancer tissues than in normal tissues and were related to poor prognosis in cancer patients. Furthermore, ferroptosis was induced under (+)-JQ1 treatment and BRD4 knockdown, indicating that (+)-JQ1 induces ferroptosis via BRD4 inhibition. Moreover, the anticancer effect of (+)-JQ1 was enhanced by ferroptosis inducers. Further studies confirmed that (+)-JQ1 induced ferroptosis via ferritinophagy, which featured autophagy enhancement by (+)-JQ1 and increased iron levels. Subsequently, the reactive oxygen species levels were increased by iron via the Fenton reaction, leading to ferroptosis. In addition, expression of the ferroptosis-associated genes GPX4, SLC7A11, and SLC3A2 was downregulated under (+)-JQ1 treatment and BRD4 knockdown, indicating that (+)-JQ1 may regulate ferroptosis by controlling the expression of ferroptosis-associated genes regulated by BRD4. Finally, (+)-JQ1 regulated ferritinophagy and the expression of ferroptosis-associated genes via epigenetic inhibition of BRD4 by suppressing the expression of the histone methyltransferase G9a or enhancing the expression of the histone deacetylase SIRT1. In summary, the BRD4 inhibitor (+)-JQ1 induces ferroptosis via ferritinophagy or the regulation of ferroptosis-associated genes through epigenetic repression of BRD4.

Indexed as

Amino Acid Transport System y+AnimalsAzepinesBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorDatabases, FactualDown-RegulationFemaleFerroptosisFusion Regulatory Protein 1, Heavy ChainHistone-Lysine N-MethyltransferaseHumansMiceMice, NudeNeoplasmsAmino Acid Transport System y+AzepinesBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsFusion Regulatory Protein 1, Heavy ChainHistone-Lysine N-Methyltransferase(+)-JQ1 compoundPhospholipid Hydroperoxide Glutathione PeroxidaseSirtuin 1SLC7A11 protein, humanTranscription FactorsTriazoles

Identifiers

PMID30988278
PMCPMC6465411
OpenAlexW2939427895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.